Identifying markers for pancreatic cyst progression and early cancer detection
Official title: Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer
Funded at Indiana University Indianapolis · NIH-11063260 · Data updated 2026-11-12
This study is looking at how certain proteins and substances in your blood and pancreatic cyst fluid can help predict if your pancreatic cysts, called IPMNs, might turn into cancer, so we can find better ways to keep an eye on them and take action sooner if needed.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $661,420 |
| NIH project number | 5U01CA239522-05 |
| Project ID | NIH-11063260 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with intraductal papillary mucinous neoplasms (IPMN) who are being monitored for potential malignant progression.
✕Less likely to help
Patients without pancreatic cysts or those who have already been diagnosed with advanced pancreatic cancer may not benefit from this research.
What this research studies
This research focuses on understanding how certain proteins and metabolites in the blood and pancreatic cyst fluid can predict the progression of pancreatic cysts, specifically intraductal papillary mucinous neoplasms (IPMN), into malignant pancreatic cancer. By analyzing samples from patients with IPMN, the study aims to identify specific biomarkers that can indicate whether these cysts are likely to become cancerous. This could lead to improved surveillance strategies and earlier interventions for patients at risk. The research involves a prospective cohort of patients and utilizes advanced proteomic and metabolomic techniques to gather and analyze data over time.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of pancreatic cancer, improving treatment outcomes and survival rates for patients.
How similar studies have gone: Previous research has shown promise in using biomarkers for cancer detection, suggesting that this approach could yield significant insights into pancreatic cancer progression.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Schmidt, Christian Maximillian — Indiana University Indianapolis
- Study coordinator: Schmidt, Christian Maximillian
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.